Sign up
Pharma Capital

Zynerba doses first patient in epilepsy gel trial

Transdermal therapeutics are absorbed through the skin directly into the systemic circulation
picture of drug being prepared
Some 180 will take part in the trial

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) has dosed its first patient in a clinical, multi-dose trial for its ZYN002 cannabidiol (CBD) gel for adults who suffer refractory focal epileptic seizures.  

The gel is designed to be transmitted through patches on the skin and as well as epilepsy is being targeted at  osteoarthritis (OA) and Fragile X syndrome (FXS).

Some 180 refractory epilepsy sufferers will be treated in the trial. After an  8-week baseline period the patients will split into three with two receiving different doses of ZYN002 and one a placebo.

The study is being conducted at 14 sites in Australia and New Zealand. Top line results are expected to be reported in the first half of 2017.

Armando Anido, Zynerba’s chief executive, said: “We are pleased by the pace of the clinical program for ZYN002 and remain on track to initiate additional Phase 2 studies in OA and FXS in the second half of this year.

“We expect to report top line results from all three studies in the first half of 2017.”

Transdermal therapeutics are absorbed through the skin directly into the systemic circulation

Approximately 2.2mln patients in the US and more in Europe and Japan are afflicted with epilepsy with focal seizures representing 35% of all epilepsy incidents.

Why Invest In Zynerba Pharmaceuticals? Read More Here

Register here to be notified of future ZYNE Company articles
View full ZYNE profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.